PRESS RELEASE - INSIDE INFORMATION | 10/06/2025

BioSenic finalises its debt restructuring efforts by obtaining the agreement of two additional private creditors to restructure over €3.9 million of debt, resulting in an overall restructuring of over €22 million of debt, subject to approval by the Enterprise Court

Mont-Saint-Guibert, Belgium, 10 June 2025 at 7:30 Am - BIOSENIC (Euronext Brussels and Paris: BIOS) announces that it has reached the final agreements required with two private creditors for the restructuring of more than €3.9 million of debt, in order to be able to consider approval of its global restructuring of more than €22 million of debt. These agreements come after (i) the agreement reached with two bondholders, announced in a press release on 18 February 2025 (available here), and (ii) the agreement with the European Investment Bank, announced in a press release on 7 April 2025 (available here), for the restructuring of more than €18 million of debt. These new agreements, together with the three other agreements mentioned above, make it possible to envisage the definitive restructuring of a total debt of more than €22 million, subject to Homologation (as defined below).

Pursuant to these two additional agreements obtained, the two private creditors concerned have in particular agreed to replace their respective claims of a cumulative amount of more than €3.9 million, as well as any interest, with cash payments totalling approximately €400,000. The agreement also provides, for one of the creditors, that any cash proceeds arising from the sale of Medsenic's assets in the context of its compulsory liquidation and accruing to BioSenic will be distributed to that creditor as well as to all other creditors who have agreed the same arrangements with BioSenic in proportion to their respective original debts.

The execution of these amicable agreements is subject in particular to their homologation by the Enterprise Court, which will be requested in the next few days, in accordance with articles XX.37 and XX.38 of the Belgian Code of Economic Law (the "Homologation"). In the event of Homologation, the terms of the reorganisation carried out last year will be adjusted accordingly for the creditors concerned.

This restructuring will be financed by the Company's future cash flow and the 21 June 2024 convertible bond programme provided by Global Tech Opportunities 15, under which €925,000 may still be drawn down subject to conditions.

Now that BioSenic has been able to reduce its debt with its main creditors (subject to Homologation), the Company can focus on continuing its development. By seeking out new projects and partnerships, BioSenic aims to leverage its expertise in the clinical development of therapies to develop innovative new therapies that address unmet medical needs and improve patient outcomes.

About BioSenic

BioSenic is a biotechnology company specialising in the clinical development of therapies for autoimmune diseases.
BioSenic is a leading biotech company specializing in the development of clinical assets issued from its Medsenic's arsenic trioxide (ATO) platform. Key target indications for the autoimmune platform include graft-versus-host-disease (GvHD), systemic lupus erythematosus (SLE), and now systemic sclerosis (SSc).
Following the merger in October 2022, BioSenic combined the strategic positionings and strengths of Medsenic and Bone Therapeutics. The merger specifically enables Medsenic/Biosenic to develop an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/oral ATO (OATO). Now that Medsenic has declared itself in cessation of payment, Biosenic will focus on new potential partnerships and the possible monetisation of its other assets (ALLOB and JTA).

BioSenic is based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium. Further information is available at http://www.biosenic.com.

About the main Medsenic/BioSenic technology platform

*The **ATO platform** provides derived active products with immunomodulatory properties and fundamental effects on the activated cells of the immune system. One direct application is its use in onco-immunology to treat GvHD (Graft-versus-Host Disease) in its chronic, established stage. cGvHD is one of the most common and clinically significant complications affecting long-term survival of allogeneic hematopoietic stem cell transplantation (allo-HSCT), a curative treatment for patients with severe blood diseases, including cancers.*

Medsenic has been successful in a phase 2 trial with its intravenous formulation, ***Arscimed®****, which has orphan drug designation status by FDA and EMA. The company was heading towards an international phase 3 confirmatory study, with its new, IP-protected, OATO formulation. Another selected target is moderate-to-severe forms of systemic lupus erythematosus (SLE), using the same oral formulation. ATO has shown good safety and significant clinical efficacy on several affected organs (skin, mucosae, and the gastrointestinal tract). Systemic sclerosis is now full part of the clinical pipeline of Medsenic/BioSenic. This serious chronic disease badly affects skin, lungs, or vascularization, and has no current effective treatment. Preclinical studies on pertinent animal models are positive, giving good grounds to launch a phase 2 clinical protocol, using new immunomodulatory formulations of APIs recognized to be active on the immune system.*

The company is currently focusing its present R&D and clinical activities on a selective, accelerated development of its autoimmune platform. However, Medsenic declared itself in cessation of payment on 18 February 2025.

For further information, please contact:

BioSenic SA
Finsys Management SRL, represented by its permanent representative Jean-Luc Vandebroek, managing director ad interim
investorrelations@biosenic.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the company or, as appropriate, the company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.